• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Troubles cognitifs dégénératifs et vasculaires - U1171
  • View Item
  •   LillOA Home
  • Liste des unités
  • Troubles cognitifs dégénératifs et vasculaires - U1171
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Influence of on-going treatment with ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1007/s00415-018-8827-6
PMID :
29549467
Permalink :
http://hdl.handle.net/20.500.12210/4309
Title :
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Author(s) :
Gilliot, Sixtine [Auteur]
Sibon, Igor [Auteur]
Mas, Jean-Louis [Auteur]
Moulin, Thierry [Auteur]
Bejot, Yannick [Auteur]
Cordonnier, Charlotte [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Giroud, Maurice [Auteur]
Odou, Pascal [Auteur] refId
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Bordet, Regis [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Vivien, Denis [Auteur]
LEYS, Didier [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Journal title :
Journal of Neurology
Abbreviated title :
J. Neurol.
Volume number :
265
Pages :
1166-1173
Publication date :
2018-05-01
ISSN :
1432-1459
Keyword(s) :
Administration
Intravenous
Aged
Aged
80 and over
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Brain Ischemia
Female
Fibrinolytic Agents
Follow-Up Studies
Humans
Intracranial Hemorrhages
Male
Middle Aged
Prospective Studies
Recombinant Proteins
Stroke
Tissue Plasminogen Activator
Treatment Outcome
Cerebral ischemia
Hemorrhagic transformation
Ischemic stroke
Mechanical thrombectomy
Neuroprotection
Outcome
Thrombolysis
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND: Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor ...
Show more >
BACKGROUND: Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset. ACE-Is and ARBs have neuroprotective properties in animal models. OBJECTIVE: To evaluate whether the 3-month outcome of patients treated with i.v. rt-PA for cerebral ischemia was influenced by on-going therapy with ACE-Is or ARBs. METHOD: This study was observational, conducted in two prospective registries of stroke patients treated with i.v. rt-PA. We evaluated outcomes with the modified Rankin scale and symptomatic intracranial hemorrhages (s-ICH) according to the ECASS2 criteria. We compared outcomes between patients with and without ACE-Is/ARBs according to the modified Rankin scale (mRS) at month 3, using logistic regression analyses adjusted on propensity scores, and propensity-matched analyses. RESULTS: Of 1803 patients, 455 (25.2%) were under ACE-Is (259), ARBs (188) or both (8). At 3 months, patients under ACE-Is or ARBs were more likely to have an mRS 0-1, but did not differ for mRS 0-2, s-ICH and death. After adjustment on propensity scores, the association between ACE-Is/ARBs and mRS 0-1 disappeared. The propensity-matched analysis, performed in 397 pairs of patients, found no difference in outcomes between patients with and without ACE-Is or ARBs. CONCLUSION: In patients treated by intravenous thrombolytic therapy for ischemic stroke, on-going treatment with ACE-Is or ARBs does not influence on outcomes after adjustment on baseline characteristics and propensity scores.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CNRS
Inserm
Collections :
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • Troubles cognitifs dégénératifs et vasculaires - U1171
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:06:56Z
Université de Lille

Mentions légales
Université de Lille © 2017